Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

Fig. 2

Frequency and titers of MOG-IgG in 614 serum samples from 522 subjects as detected using a live-cell CBA. MOG-IgG was detected in 95/386 (24.6%) samples in group I but was almost completely absent among 228 control samples (groups II–IV), including 89 samples from AQP4-IgG-positive patients, 85 samples from patients with MS according to the McDonald criteria (group III), and 54 samples from healthy controls and OND patients (group IV). While all low-titer samples (1:160–1:320) in group I were positive also in the fixed-cell CBA, the only positive control sample (from group IV) was negative in the fixed-cell CBA, suggesting a false-positive test result. The horizontal dashed line indicates the assay-specific cut-off (> = 1:160)

Back to article page